Article Tools

Search for Related Articles

Announcements

CID LISTED AMONG
“MOST INFLUENTIAL”

Clinical Infectious Diseases has been named as one of the "100 Most Influential Journals in Biology and Medicine" of the past 100 years by the Special Libraries Association. The list was compiled by the 680-plus members of SLA’s Biomedical and Life Sciences Division.

See the full list here.

Source: The DBIO 100, the 100 Most Influential Journals in Biology & Medicine over the last 100 Years

In the News

Featured in MSNBC
"Germs and flu are up; infection control is down" June 9, 2009
Trends in the Incidence of Methicillin‐Resistant Staphylococcus aureus Infection in Children’s Hospitals in the United States
Jeffrey S. Gerber, Susan E. Coffin, Sarah A. Smathers, and Theoklis E. Zaoutis
Just this week, researchers reported that the incidence of MRSA infections among children admitted to pediatric hospitals in the United States more than tripled between 2002 and 2007. Researchers at the Children’s Hospital of Philadelphia and the University of Pennsylvania found cases of MRSA jumped from 6.7 per 1,000 admissions in 2002 to 21.1 cases per 1,000 admissions in 2007, according to a study released online Monday in the journal Clinical Infectious Diseases.

Featured in Toronto Star
"Pigs, viruses and politics" May 2, 2009
Are Swine Workers in the United States at Increased Risk of Infection with Zoonotic Influenza Virus?
Kendall P. Myers, Christopher W. Olsen, Sharon F. Setterquist, Ana W. Capuano, Kelley J. Donham, Eileen L. Thacker, James A. Merchant, and Gregory C. Gray
Another study, this one published in the U.S. journal Clinical Infectious Diseases in 2006, found that workers in meat-processing plants have a greater likelihood of being infected by some version of the H1N1 flu virus than the general population (the odds of pig farmers getting the disease are significantly greater again).

Featured in Philadelphia Inquirer
"A shot in the arm for vaccines" April 19, 2009
Vaccines: Pneumococcal Vaccination of Elderly Adults: New Paradigms for Protection
Lisa A. Jackson and Edward N. Janoff
Every year, an estimated 915,000 people 65 and older get pneumonia, and 40 percent of them end up in hospitals, according to a 2004 paper in the journal Clinical Infectious Diseases. Pneumonia often kills older people, said Richard Stefanacci, a geriatrician at the University of the Sciences in Philadelphia.

15 September 2007 Supplement

Volume 45, Number S3
Clinical Infectious Diseases 2007;45:S184–S190
1058-4838/2007/4506S3-0005$15.00
DOI: 10.1086/519471
SUPPLEMENT ARTICLE

Alternatives to Vancomycin for the Treatment of Methicillin‐Resistant Staphylococcus aureus Infections

Scott T. Micek

Department of Pharmacy, Barnes‐Jewish Hospital, St. Louis, Missouri

Vancomycin remains the reference standard for the treatment of systemic infection caused by methicillin‐resistant Staphylococcus aureus (MRSA). However, as a result of limited tissue distribution, as well as the emergence of isolates with reduced susceptibility and in vitro resistance to vancomycin, the need for alternative therapies that target MRSA has become apparent. New treatment options for invasive MRSA infections include linezolid, daptomycin, tigecycline, and quinupristin/dalfopristin. Additionally, a number of new anti‐MRSA compounds are in development, including novel glycopeptides (dalbavancin, telavancin, and oritavancin), ceftobiprole, and iclaprim. The present article will review clinical issues surrounding the newly marketed and investigational agents with activity against MRSA.

Reprints or correspondence: Dr. Scott T. Micek, Dept. of Pharmacy, Barnes‐Jewish Hospital, Mailstop 90‐52‐411, 216 S. Kingshighway Blvd., St. Louis, MO ().

Cited by

Hee‐Chang Jang, Sung‐Han Kim, Kye Hyoung Kim, Choong Jong Kim, Shinwon Lee, Kyoung‐Ho Song, Jae Hyun Jeon, Wan Beom Park, Hong Bin Kim, Sang‐Won Park, Nam Joong Kim, Eui‐Chong Kim, Myoung‐don Oh, and Kang Won Choe. (2009) Salvage Treatment for Persistent Methicillin‐Resistant Staphylococcus aureus Bacteremia: Efficacy of Linezolid With or Without Carbapenem. Clinical Infectious Diseases 49:3, 395-401
Online publication date: 1-Aug-2009.
, O. Gallon, C. Guillet-Caruba, B. Lamy, F. Laurent, F. Doucet-Populaire, J.-W. Decousser. (2009) In vitro activity of daptomycin against Staphylococci isolated from bacteremia and community-onset skin and soft tissue infections in France: data from two nationwide studies. European Journal of Clinical Microbiology & Infectious Diseases
Online publication date: 6-Jul-2009.
CrossRef
Amy M. Creel, Spencer H. Durham, Kim W. Benner, Jeffrey A. Alten, Margaret K. Winkler. (2009) Severe invasive community-associated methicillin-resistant Staphylococcus aureus infections in previously healthy children *. Pediatric Critical Care Medicine 10:3, 323-327
Online publication date: 1-Jun-2009.
CrossRef
Kenneth V. I. Rolston. (2009) New antimicrobial agents for the treatment of bacterial infections in cancer patients. Hematological Oncology n/a-n/a
Online publication date: 1-Feb-2009.
CrossRef
Knut Ohlsen, Gudrun Dandekar, Roland Schwarz, Thomas Dandekar. (2008) New trends in pharmacogenomic strategies against resistance development in microbial infections. Pharmacogenomics 9:11, 1711-1723
Online publication date: 1-Dec-2008.
CrossRef
Lena M. Napolitano. (2008) Early Appropriate Parenteral Antimicrobial Treatment of Complicated Skin and Soft Tissue Infections Caused by Methicillin-Resistant Staphylococcus aureus. Surgical Infections 9:s1, s17-s27
Online publication date: 1-Nov-2008.
CrossRef
Natasha VDV Ratnaraja, Peter M Hawkey. (2008) Current challenges in treating MRSA: what are the options?. Expert Review of Anti-infective Therapy 6:5, 601-618
Online publication date: 1-Nov-2008.
CrossRef
G. Fritsche, G. Weiss. (2008) Therapeutic options for the treatment of infections with multiresistant grampositive bacteria in oncological patients. memo - Magazine of European Medical Oncology 1:3, 177-180
Online publication date: 1-Oct-2008.
CrossRef
Andreas M Lenz, Mark Fairweather, William G Cheadle. (2008) Resistance profiles in surgical-site infection. Future Microbiology 3:4, 453-462
Online publication date: 1-Sep-2008.
CrossRef
AJ O'Neill. (2008) New antibacterial agents for treating infections caused by multi-drug resistant Gram-negative bacteria. Expert Opinion on Investigational Drugs 17:3, 297-302
Online publication date: 1-Apr-2008.
CrossRef
Andreas F. Widmer. (2008) Editorial Commentary: Ceftobiprole: A New Option for Treatment of Skin and Soft‐Tissue Infections due to Methicillin‐Resistant Staphylococcus aureus. Clinical Infectious Diseases 46:5, 656-658
Online publication date: 1-Mar-2008.
Garyphallia Poulakou, Helen Giamarellou. (2008) Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens. Expert Opinion on Investigational Drugs 17:2, 225-243
Online publication date: 1-Mar-2008.
CrossRef
Close Popup